Trial Profile
Safety and Relative Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules Charge 1 Compared to BIBF 1120 Soft Gelatine Capsules Charge 2 Compared to BIBF 1120 Administered as Drinking Solution Following Oral Administration to Healthy Male Volunteers in an Open, Randomised, Intra-individual, Crossover Comparison Design
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2014
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Nintedanib (Primary)
- Indications Colorectal cancer; Idiopathic pulmonary fibrosis; Liver cancer; Mesothelioma; Non-small cell lung cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 16 Jul 2014 New trial record